Program Description & Educational Objectives

In this activity, experts in the management of lymphoproliferative malignancies, including non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL), discuss the relevance of new data presented and published in 2011 for patient care, including (but not limited to) findings presented at the annual meetings of the American Society of Clinical Oncology and European Hematology Association.

Upon completion of this activity, participants should be better able to:

• Plan a tailored management strategy for patients with indolent or aggressive non Hodgkin’s lymphoma (NHL) or chronic lymphocytic leukemia (CLL)
• Employ new data on novel therapeutic options in the management of newly diagnosed or relapsed/refractory indolent lymphoma
• Apply recent clinical trial findings when developing treatment plans for patients with aggressive NHL, including large-cell and mantle-cell lymphoma
• Evaluate the clinical potential of developmental agents being investigated in lymphoproliferative cancers, including indolent and aggressive NHL and CLL
• Summarize and/or apply new data on modified first- and second-line treatment strategies for different CLL populations

Target Audience

This activity has been designed to meet the educational needs of hematologists, hematologist-oncologists and other clinicians involved in the management of patients with lymphoproliferative malignancies.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Internet
Release and Expiration Dates: November 22, 2011 - November 21, 2012
Time to Complete: 30 minutes

Faculty & Disclosure / Conflict of Interest Policy

In accordance with ACCME requirements, the University of New Mexico Health Sciences Center, School of Medicine, has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced. The relationships were reviewed by UNM CME and conflicts of interest were resolved prior to the activity.

Course Director and Interviewee

John P. Leonard, MD
Professor of Medicine
Weill Cornell Medical College
Attending Physician
New York–Presbyterian Hospital
New York, New York

John P. Leonard, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for Abbott Laboratories; Biotest Pharmaceuticals Corporation; Calistoga Pharmaceuticals, Inc./Gilead; Celgene Corporation; Cell Therapeutics, Inc.; Cephalon, Inc.; GlaxoSmithKline; Hospira, Inc.; Immunomedics, Inc.; Johnson & Johnson Services, Inc.; MedImmune, LLC; Millennium Pharmaceuticals, Inc.; MorphoSys; sanofi-aventis; and Seattle Genetics, Inc.

Interviewee

Michael Keating, MBBS
Professor of Medicine
Leukemia Department
The University of Texas M. D. Anderson Cancer Center
Houston, Texas

Michael Keating, MBBS, currently has no financial interests/relationships or affiliations in relation to this activity.

Content Director

Carmine DeLuca
PVI, PeerView Institute for Medical Education

Carmine DeLuca currently has no financial interests/relationships or affiliations in relation to this activity.

Sponsorship, Credit & Support

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the University of New Mexico Health Sciences Center, School of Medicine and PVI, PeerView Institute for Medical Education. The University of New Mexico Health Sciences Center, School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The University of New Mexico Health Sciences Center, School of Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This CME activity is jointly sponsored by the University of New Mexico Health Sciences Center, School of Medicine and PVI, PeerView Institute for Medical Education.

This activity is supported by educational grants from Genentech, Inc. and Spectrum Pharmaceuticals, Inc.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.

Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.